Business, energy, technology, markets and global industry news from Business News Today

ENDO 2026

PharmaDeviceNews ENDO 2026
Pharma & Biotech

Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care

Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.

Read More
Pharma & Biotech

Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?

Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.

Read More
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Representative image of an endocrinology researcher reviewing adrenal hormone data, as Neurocrine Biosciences’ Crenessity update at ENDO 2026 raises new questions about treatment options for classic congenital adrenal hyperplasia.
Pharma & Biotech

Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?

Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.

Read More
Representative image: A pediatric rare disease consultation highlights how VYKAT XR data could reshape long-term hyperphagia treatment in Prader-Willi syndrome.
Pharma & Biotech

Soleno Therapeutics VYKAT XR data strengthens long-term case in Prader-Willi syndrome

Find out how Soleno Therapeutics’ VYKAT XR data could reshape hyperphagia treatment in Prader-Willi syndrome.

Read More
Representative image of a clinical researcher reviewing liver imaging and lipid test results, reflecting OrsoBio’s TLC-2716 Phase 2a data in severe hypertriglyceridemia and MASLD.
Pharma & Biotech

OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease

Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.

Read More
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More
Pharma & Biotech

Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody

Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.

Read More